NSEUpdates3 Aug 2026 · 3 Aug 2026, 05:36 pm
Updates
Piramal Pharma Limited · PPLPHARMA
✦ AI SummaryRegulatory
Piramal Pharma Limited has resumed operations at its facilities in Ahmedabad, Gujarat, after a temporary suspension due to heavy rainfall and flooding. The company has completed a preliminary assessment and initiated the insurance claim process, with no material impact expected on its operations or financial performance.
Analysis Scores
Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk8/10
Balance Sheet Risk3/10
Liquidity Impact8/10
Market Sentiment5/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Resumption of operations at Company s facilities located at Ahmedabad, Gujarat
Attachments (1)
📄pdf
Download →
PIRAMALPHARMA_03082026173517_Reg_30_Intimation_-_Resumption_of_operation.pdf
View document text
3rd August, 2026
BSE Limited National Stock Exchange of India Limited
P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex,
Mumbai- 400 001 Bandra (East), Mumbai – 400 051
BSE scrip code: 543635 NSE symbol: PPLPHARMA
Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015 – Resumption of operations at Company’s facilities
located at Ahmedabad, Gujarat
Dear Sir / Madam,
This is further to our communication dated 24th July, 2026, regarding temporary suspension
of operations at the Company's manufacturing facilities located at Plot Nos. 18 and 19 –
PHARMEZ - Pharmaceutical Special Economic Zone, Village Matoda, Sarkhej Bawla, NH
8A, Taluka Sanand, Ahmedabad - 382 213, Gujarat, India, due to exceptionally heavy rainfall
and flooding across parts of Gujarat.
We wish to inform you that operations have resumed across substantially all areas of the
aforesaid facilities, with only limited restoration and recommissioning activities ongoing in
certain sections.
The Company has completed a preliminary assessment of the impact on its assets and
operations and has initiated the insurance claim process. Based on the assessment undertaken
to date, the Company does not expect any material impact on its operations or financial
performance.
This is for your information and records
Thank you.
Yours truly,
For Piramal Pharma Limited
Maneesh Sharma
Company Secretary & Compliance Officer
Piramal Pharma Limited
CIN: L24297MH2020PLC338592
Registered Office: Ananta Building, Piramal Corporate Park, Opp. Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070, Maharashtra, India
Tel No. +91 22 3802 3000 / 4000; Email Id: shareholders.ppl@piramal.com
www.piramalpharma.com